Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Gastrointestinal 5 Breast 5 Tumor-Agnostic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 62 Paclitaxel 51 Gemcitabine 50 Carboplatin 45 Docetaxel 43 Cisplatin 31 Pemetrexed 30 Nivolumab 28 Bevacizumab 28 atezolizumab 22 Fluorouracil 22 Cetuximab 21 Capecitabine 21 Irinotecan 20 Leucovorin 19 Afatinib 18 Erlotinib Hydrochloride 15 trametinib 14 Trastuzumab 13 Ipilimumab 13 130-nm albumin-bound paclitaxel 13 regorafenib 11 olaparib 11 Sorafenib 11 Oxaliplatin 11 Drug Therapy 11 eribulin 10 enzalutamide 10 Midazolam 10 Injections 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × patritumab deruxtecan × Tumor-Agnostic × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡